Valuation: Charles River Laboratories International, Inc.

Market Cap 13.05B 11.37B 10.76B 9.78B 18.26B 1,250B 18.35B 128B 49.55B 635B 49.03B 47.94B 2,034B P/E 2026 *
73.1x
P/E 2027 * 31.4x
Enterprise Value 15.16B 13.21B 12.5B 11.36B 21.22B 1,452B 21.32B 149B 57.57B 738B 56.97B 55.7B 2,363B EV / Sales 2026 *
3.88x
EV / Sales 2027 * 3.67x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
09:24am Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization CI
08:25am Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
Sep. 16 Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says MT
Sep. 15 Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
Sep. 14 Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
Sep. 11 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
Sep. 08 Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite CI
Aug. 20 Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing MT
Aug. 20 Charles River, Medigen Partner on Multivalent Enterovirus Vaccine MT
Aug. 20 Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing CI
Aug. 13 Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing MT
Aug. 10 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
Aug. 10 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
1 day+2.07%
1 week+0.87%
Current month-2.06%
1 month+0.86%
3 months+53.01%
1 week 222.17
Extreme 222.169
227.95
1 month 221.61
Extreme 221.613
242.28
Current year 146.62
Extreme 146.619
242.28
1 year 146.62
Extreme 146.619
242.28
3 years 146.62
Extreme 146.619
242.28
5 years 146.62
Extreme 146.619
242.28
10 years 146.62
Extreme 146.619
242.28
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%+0.87% - - 13.05B
+1.23%+1.30%-0.69%+9.57% 45.91B
+0.23%+4.72%+44.32%+28.70% 44.25B
+0.52%-3.15%+349.53%+536.73% 41.99B
+1.55%+3.41%+6.40%+69.19% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
-0.20%+5.49%+23.57%+125.26% 17.21B
-3.49%-8.49% - - 16.27B
+2.92%+8.37%+22.73%+38.87% 14.96B
-2.45%+2.41%-3.16%-35.49% 13.42B
Average +0.52%+1.54%+56.87%+101.74% 29.41B
Weighted average by Cap. +0.83%+0.68%+72.24%+122.89%

Financials

2026 *2027 *
Net sales 3.91B 3.41B 3.22B 2.93B 5.47B 375B 5.5B 38.4B 14.85B 190B 14.69B 14.37B 609B 4B 3.48B 3.3B 3B 5.6B 383B 5.63B 39.28B 15.19B 195B 15.03B 14.69B 623B
Net income 162M 141M 134M 122M 227M 15.55B 228M 1.59B 616M 7.9B 610M 596M 25.3B 428M 373M 353M 320M 598M 40.96B 601M 4.2B 1.62B 20.82B 1.61B 1.57B 66.64B
Net Debt 2.11B 1.84B 1.74B 1.58B 2.96B 202B 2.97B 20.74B 8.02B 103B 7.93B 7.76B 329B 1.63B 1.42B 1.34B 1.22B 2.28B 156B 2.29B 16.01B 6.19B 79.37B 6.13B 5.99B 254B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
26-09-16 CHF 226.97 +2.07%
26-09-15 CHF 222.36 +0.09%
26-09-14 CHF 222.17 -2.54%
26-09-11 CHF 227.95 +2.86%
26-09-10 CHF 221.61 -1.51%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
273.41USD
Average target price
282.43USD
Spread / Average Target
+3.30%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!